Sorrento, Yuhan JV to start Korean trials of anti-PD-L1 mAb

Sorrento Therapeutics Inc. (NASDAQ:SRNE) said the South Korean Ministry of Food and Drug Safety (MFDS) approved an IND to begin Phase I testing of STI-A1015 (IMC-001) to treat solid tumors. STI-A1015 is a mAb against PD-L1.

ImmuneOncia Therapeutics Inc., a JV between Sorrento and Yuhan Corp. (KSE:000100), has exclusive rights to the candidate from Sorrento in regions outside the U.S., EU and Japan...